12:00 AM
 | 
Apr 15, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lucentis ranibizumab regulatory update

The U.K.'s NICE issued a final appraisal determination recommending Lucentis ranibizumab from Novartis to treat macular edema secondary to central retinal vein occlusion (CRVO) and for macular edema secondary to branch retinal vein occlusion (BRVO) for a subset of patients for whom laser photocoagulation has not worked or is not suitable. The recommendation, which is contingent on Novartis providing Lucentis at...

Read the full 285 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >